How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,200 results for

E/M Medical Decision Making

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

9141. An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options

treatment options. Condition or disease Intervention/treatment Chronic Hepatitis B Drug: Adefovir Dipivoxil Detailed Description: Due to the considerable unmet medical need of patients with chronic hepatitis B, Gilead has initiated an early access program to make its investigational drug, adefovir dipivoxil 10 mg, available to those patients with lamivudine-resistant chronic hepatitis B at risk of disease progression. Protocol GS-01-550 provides access to patients with lamivudine-resistant hepatitis B (...) prior to starting treatment with adefovir dipivoxil. Currently enrolled in another clinical trial of adefovir dipivoxil. HIV and HBV co-infected patients receiving tenofovir disoproxil fumarate [Viread(R)] for their HIV disease. Pregnant or lactating females. Contacts and Locations Go to No Contacts or Locations Provided More Information Go to Publications: Perrillo R, Schiff E, Hann H-W L, Buti M, Strasser S, Watkins KM, Moorat AE, Woessner MA, Vig P, Brosgart CL, Bourne EC, and Atkins MC

2002 Clinical Trials

9142. A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas

Results First Posted : February 13, 2012 Last Update Posted : February 13, 2012 Sponsor: National Cancer Institute (NCI) Information provided by: National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: Diffuse pontine gliomas are tumors on the pons portion of the brainstem. Their peak incidence is in children between 5 and 10 years old. Their location makes surgical resection impossible. Most patients are treated with radiation, which typically delays (...) ) for a 4-week cycle. The cycles will be repeated indefinitely until progression of disease or serious side effects develop. For less severe effects, the dose will be lowered and the patient may remain in the study. For more severe effects, the dose will be discontinued. Patients in the study may receive supportive medication but may not receive other forms of chemotherapy. Patients or their caregivers will be instructed in how to inject the drug. Patients and/or caregivers will be asked to maintain

2002 Clinical Trials

9143. Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment Naive Adults With Chronic Hepatitis B Virus Infection

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Adults (...) >= 18 years of age Chronic HBV infection, known to be HbsAg positive >= 6 months Plasma HBV DNA level >= 100,000 copies/mL HBe-antigen positive HIV negative Basic hematologic and chemistry parameters within acceptable limits (defined in protocol No need for excluded medications Subjects of reproductive capability must utilize two approved forms of birth control, one of which must be barrier protection. Exclusion Criteria: HIV infection Hepatitis C co-infection Concurrent systemic antiviral treatment

2002 Clinical Trials

9144. Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

mg/m^2; Final Dose: Not Established Drug: ATV Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in. Experimental: Step I: Group 2 Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs. ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established Drug (...) : ATV Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in. Experimental: Step I: Group 3 Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs. ATV Dose Tested: 310 mg/m^2, 415 mg/m2, 520 mg/m^2; Final Dose: 520 mg/m^2 Drug: ATV Participants received varying

2000 Clinical Trials

9145. Specialized Center of Research in Occupational and Immunologic Lung Disease

. In: Fishman A (Ed), Pulmonary Diseases and Disorders. New York: McGraw-Hill, 1980 Weill H: Basis for Clinical Decision Making (Asbestos Symposium). In: Proceedings of First International Conference on Occupational Lung Disease, 1979. Published in Chest, 78(2):382-383, 1980 Stankus RP, Doll NJ, Salvaggio JE: Humoral and Cellular Enhancement in Experimental and Human Silicosis. In: Boros D and Yoshida T (Eds), Basic and Clinical Aspects of Granulomatous Disease. New York: Elsevier Publishing Co. 305-315 (...) Problems in Internal Medicine. New York: Medical Examination Publishing Co. Inc. (in press, 1985) Rando RJ, Hammad YY: Filter Collection of Airborne Permethrin with Determination by HPLC. J Liquid Chromatogr, 8:1869-1880, 1985 Stankus RP: Bronchopulmonary Lavage in the Diagnosis of Pulmonary Immune Disease. In: McMann E (Ed), Principles and Techniques of Human Research and Therapeutics. Futura, 37-50, 1985 Stankus RP, Salvaggio JE: Immunodiagnostic Techniques in Human Lung Research: Bronchoalveolar

2000 Clinical Trials

9146. Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well fludarabine and cyclophosphamide followed by peripheral stem cell transplant works in treating patients with leukemia or lymphoma. Condition or disease Intervention/treatment Phase Leukemia (...) Experimental: Allogeneic Stem Cell Tx minimal ablation and cellular immune therapy with allogeneic donor stem cell therapy Drug: fludarabine phosphate 30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3) Drug: Cyclophosphamide 1 g/sq m/day IV infusion x 3 days (Days -5 thru -3) Biological: PBSC 2-8,000,000/kg CD34+ cells via infusion on Day 0 Drug: G-CSF 5 ug/kg/day subQ injection until ANC > 1000/uL for 3 days beginning Day 5 Biological: Donor lymphocytes 10,000,000 CD3+ cells/kg via infusion Outcome

2000 Clinical Trials

9147. Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myeloid, Chronic Drug: Zarnestra (R115777) Drug: Gleevec (Imatinib mesylate) Phase 1 Detailed Description: R115777 is a new drug that blocks the function of an enzyme that is important in making some proteins work. One of the most important targets for this enzyme is a protein that can make cells become cancer. Imatinib mesylate is a drug that blocks the function of the protein that comes from the Philadelphia chromosome. The Philadelphia chromosome is an abnormality in chromosomes 9 and 22 (...) of these medications that participants take will depend on when they enter the study. The doses will be slowly increased from participant to participant until the highest dose that does not cause serious side effects is found. Participants will be asked to visit their doctor for a physical exam and measurement of vital signs. The frequency of doctor visits will vary depending on physical condition. Blood tests (about 2 teaspoons each) will be done every week during the first 3 weeks of treatment. Blood tests

2002 Clinical Trials

9148. Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases

-organ dysfunctions, particularly neurologic deficits detectable by clinical examination or significant intellectual impairment in metabolic disorders Evidence of active infection (including urinary tract infection, or upper respiratory tract infection) or hepatitis (on screening). Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis. Factors that place the donor at increased risk for complications from leukapheresis or G-CSF (...) 2009 Actual Study Completion Date : June 2009 Resource links provided by the National Library of Medicine resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: CD34 PBPC CD34 peripheral blood progenitor cell (PBPC) transplants in 3 groups: 1) HLA-matched Sibling Transplant Patients; 2) Unrelated Donor Transplant Patients; 3) Haplo Identical Transplant Patients. Preparative regimen is 140 mg/m^2 Melphalan on day -8, 10 mg/kg Thiotepa on day -7, 160 mg/m^2 Fludarabine over

2002 Clinical Trials

9149. Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

tobacco smoker Known inability to participate in the scheduled follow-up tests (i.e., alcohol dependence or illicit drug use) Significant medical history or psychiatric problems which would make the participant a poor protocol candidate, in the opinion of the principal investigator Post surgical removal of both ovaries Postmenopausal women with amenorrhea greater than 12 months Previous history of endometrial biopsy, hysteroscopy, dilatation and curettage, or IUD in place within the past 3 months (...) ) in the absence of unacceptable toxicity. Approximately 1 week after starting the fourth pack of OCP, patients undergo a repeat transvaginal ultrasound and endometrial biopsy. Drug: ethinyl estradiol Given orally Other Names: Diogyn E EE Estinyl Ethinoral Eticylol Drug: norgestrel Given orally Other Names: Microlut NORGES Ovrette Wy-3707 Other: laboratory biomarker analysis Correlative studies Outcome Measures Go to Primary Outcome Measures : Change in potential SEBs relevant to endometrial carcinogenesis

2002 Clinical Trials

9150. A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth

Durham, North Carolina, United States, 277103499 Sponsors and Collaborators National Institute of Allergy and Infectious Diseases (NIAID) Glaxo Wellcome Investigators Layout table for investigator information Study Chair: Modlin J More Information Go to Publications: Vance E, Guzman J, Bitar M, Kazanjian P. Clarithromycin and zidovudine pharmacokinetic study. Int Conf AIDS. 1994 Aug 7-12;10(2):201 (abstract no PB0816) Layout table for additonal information ClinicalTrials.gov Identifier: Other Study (...) to make sure the drug is not having a toxic effect on the child. A single cerebrospinal fluid (CSF) sample is taken from the last 12 children entering the study, so that the level of the AZT reaching the brain can be measured. The child returns to the hospital or clinic 4 weeks after the end of therapy to make sure that there are no delayed toxic effects. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 18 participants Masking: None (Open

1999 Clinical Trials

9151. A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)

urinalysis. Prior Medication: Required: Two prior doses of HIVAC-1e (or DryVax) and two prior doses of gp160 vaccine. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Risk factors for HIV infection including active intravenous drug use and more than 2 sexual partners. History of immunodeficiency or chronic illness. Hypersensitivity to insects. Medical or psychiatric condition that makes it unlikely the patient will comply with the protocol (...) to Publications: McElrath J, Peterson E, Dragavon J, Berger D, Hoffman M, Klucking S, Greenberg P, Corey L. Combination prime-boost approach to HIV vaccination in seronegative individuals: enhanced immunity with additional subunit gp160 protein boosting. Int Conf AIDS. 1992 Jul 19-24;8(1):Mo9 (abstract no MoB 0027) Layout table for additonal information Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID) ClinicalTrials.gov Identifier: Other Study ID Numbers: AVEG 002B 10539

1999 Clinical Trials

9152. An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies

Seattle, Washington, United States, 981224304 Sponsors and Collaborators National Institute of Allergy and Infectious Diseases (NIAID) Investigators Layout table for investigator information Study Chair: Feinberg J More Information Go to Publications: Katz D, Feinberg J, Myers M, Gubish E, Hoth D. Providing access to promising investigational drugs for AIDS: A management model for "treatment INDs". Int Conf AIDS. 1989 Jun 4-9;5:855 (abstract no TEP51) Feinberg J, Katz D, McDermott C, Myers M, Hoth D (...) Completion Date : July 2004 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using

1999 Clinical Trials

9153. Withholding and withdrawing life sustaining treatment in neonatal intensive care: issues for the 1990s. (PubMed)

A A Frader J J Hack M M Korones S S Merenstein G G Paneth N N Poland R L RL Saigal S S eng Case Reports Journal Article Research Support, Non-U.S. Gov't England Arch Dis Child Fetal Neonatal Ed 9501297 1359-2998 AIM E IM Decision Making Dissent and Disputes Ethics Committees, Clinical Ethics, Medical Female Group Processes Humans Infant, Low Birth Weight Infant, Newborn Infant, Premature Intensive Care, Neonatal Male Medical Futility Parents Patient Selection Refusal to Treat Resource Allocation (...) Withholding and withdrawing life sustaining treatment in neonatal intensive care: issues for the 1990s. 7820723 1995 02 16 2018 11 13 1359-2998 71 3 1994 Nov Archives of disease in childhood. Fetal and neonatal edition Arch. Dis. Child. Fetal Neonatal Ed. Withholding and withdrawing life sustaining treatment in neonatal intensive care: issues for the 1990s. F218-23 Lantos J D JD MacLean Center for Clinical Medical Ethics, University of Chicago Pritzker School of Medicine. Tyson J E JE Allen

Full Text available with Trip Pro

1994 Archives of disease in childhood Fetal and neonatal edition

9154. What do Canadian MDs think about euthanasia? An update following the CMA annual meeting. (PubMed)

What do Canadian MDs think about euthanasia? An update following the CMA annual meeting. 7904894 1994 03 01 2018 11 30 0820-3946 150 3 1994 Feb 01 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ What do Canadian MDs think about euthanasia? An update following the CMA annual meeting. 395-7 Sawyer D M DM eng Congress Canada CMAJ 9711805 0820-3946 AIM E IM CMAJ. 1994 Aug 1;151(3):267 8039071 Canada Decision Making Ethics, Medical Euthanasia Humans (...) 45092 Canadian Medical Association Death and Euthanasia Empirical Approach KIE Bib: euthanasia/attitudes; suicide 1994 2 1 1994 2 1 0 1 1994 2 1 0 0 ppublish 7904894 PMC1486165 BMJ. 1992 Feb 15;304(6824):434-6 1547394 Lancet. 1991 Sep 14;338(8768):669-74 1715962 Lancet. 1993 May 8;341(8854):1196-9 8098087 CMAJ. 1993 Jun 1;148(11):1921-6 8500029

Full Text available with Trip Pro

1994 CMAJ: Canadian Medical Association Journal

9155. How ethics consultation can help resolve dilemmas about dying patients. (PubMed)

How ethics consultation can help resolve dilemmas about dying patients. 7571590 1995 11 21 2018 11 13 0093-0415 163 3 1995 Sep The Western journal of medicine West. J. Med. How ethics consultation can help resolve dilemmas about dying patients. 263-7 La Puma J J Division of General Internal Medicine, Medical College of Wisconsin, Milwaukee, USA. Schiedermayer D D Siegler M M eng Journal Article United States West J Med 0410504 0093-0415 AIM E IM Comprehension Decision Making Dissent (...) and Disputes Ethicists Ethics Consultation Ethics, Clinical Ethics, Medical Group Processes Humans Professional Role Quality of Life Referral and Consultation Resource Allocation Risk Assessment Social Values Terminal Care Withholding Treatment 49776 Bioethics and Professional Ethics Death and Euthanasia KIE BoB Subject Heading: allowing to die KIE BoB Subject Heading: ethicists and ethics committees KIE BoB Subject Heading: terminal care Full author name: La Puma, John Full author name: Schiedermayer

Full Text available with Trip Pro

1995 Western Journal of Medicine

9156. Psychological effects of being offered choice of surgery for breast cancer. (PubMed)

-8138 AIM E IM BMJ. 1994 Oct 8;309(6959):955 7950679 Anxiety etiology Breast surgery Breast Neoplasms psychology surgery Choice Behavior Decision Making Depression etiology England Female Humans Mastectomy methods psychology Patient Participation psychology Personal Autonomy Physician-Patient Relations Prospective Studies Risk Assessment Risk Factors 45963 Empirical Approach Professional Patient Relationship Commented on by S.L. Turner and E.J. Maher, "Information and choice in decisions about (...) Psychological effects of being offered choice of surgery for breast cancer. 7920129 1994 10 27 2018 11 13 0959-8138 309 6952 1994 Aug 13 BMJ (Clinical research ed.) BMJ Psychological effects of being offered choice of surgery for breast cancer. 448 Fallowfield L J LJ Department of Oncology, University College London Medical School. Hall A A Maguire P P Baum M M A'Hern R P RP eng Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. England BMJ 8900488 0959

Full Text available with Trip Pro

1994 BMJ : British Medical Journal

9157. Ethics and evidence based medicine (PubMed)

Ethics and evidence based medicine 9552959 1998 05 12 2018 11 13 0959-8138 316 7138 1998 Apr 11 BMJ (Clinical research ed.) BMJ Ethics and evidence based medicine. 1151-3 Kerridge I I Lowe M M Henry D D eng Journal Article Review England BMJ 8900488 0959-8138 AIM E IM Australia Bias Clinical Trials as Topic Data Collection Decision Making Empirical Research Ethics, Medical Evidence-Based Medicine standards Health Care Rationing Humans Randomized Controlled Trials as Topic Resource Allocation

Full Text available with Trip Pro

1998 BMJ : British Medical Journal

9158. Withholding and withdrawal of life support from critically ill patients. (PubMed)

Withholding and withdrawal of life support from critically ill patients. 9426480 1998 02 10 2018 11 13 0093-0415 167 6 1997 Dec The Western journal of medicine West. J. Med. Withholding and withdrawal of life support from critically ill patients. 411-6 Luce J M JM Department of Medicine, University of California, San Francisco, USA. eng Journal Article Review United States West J Med 0410504 0093-0415 AIM E IM Critical Illness therapy Decision Making Dissent and Disputes Empirical Research (...) Ethics, Medical Euthanasia, Passive Group Processes Humans Life Support Care legislation & jurisprudence standards Physician-Patient Relations Resource Allocation Resuscitation Orders legislation & jurisprudence Withholding Treatment 32 63362 Death and Euthanasia Society of Critical Care Medicine KIE BoB Subject Heading: allowing to die Full author name: Luce, John M 1998 1 14 1998 1 14 0 1 1998 1 14 0 0 ppublish 9426480 PMC1304720 N Engl J Med. 1990 Feb 1;322(5):309-15 2296273 JAMA. 1990 Feb 2;263(5

Full Text available with Trip Pro

1997 Western Journal of Medicine

9159. Psychological responses to genetic testing (PubMed)

Psychological responses to genetic testing 9522800 1998 04 16 2018 11 13 0959-8138 316 7132 1998 Feb 28 BMJ (Clinical research ed.) BMJ The new genetics. Psychological responses to genetic testing. 693-6 Marteau T M TM Psychology and Genetics Research Group, United Medical School, Guy's Hospital, London. Croyle R T RT eng Wellcome Trust United Kingdom Journal Article Research Support, Non-U.S. Gov't Review England BMJ 8900488 0959-8138 AIM E IM BMJ. 1998 Aug 8;317(7155):417 9694776 BMJ. 1998 (...) Aug 15;317(7156):471 9703537 Attitude to Health Decision Making Family Genetic Diseases, Inborn Genetic Testing methods psychology Humans Interpersonal Relations Public Opinion Uncertainty 34 57756 Genetics and Reproduction KIE BoB Subject Heading: genetic counseling KIE BoB Subject Heading: genetic screening Full author name: Marteau, Theresa M Full author name: Croyle, Robert T 1998 4 2 1998 4 2 0 1 1998 4 2 0 0 ppublish 9522800 PMC1112686 Am J Hum Genet. 1994 Oct;55(4):626-37 7942840 Am J Med

Full Text available with Trip Pro

1998 BMJ : British Medical Journal

9160. DNR orders in stroke. (PubMed)

DNR orders in stroke. 8705905 1996 09 10 2018 11 13 0820-3946 155 3 1996 Aug 01 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ DNR orders in stroke. 276-7 Alexandrov A V AV Meslin E M EM eng Letter Canada CMAJ 9711805 0820-3946 AIM IM Acute Disease Cerebrovascular Disorders therapy Decision Making Humans Medical Futility Practice Guidelines as Topic Resuscitation Orders 1996 8 1 1996 8 1 0 1 1996 8 1 0 0 ppublish 8705905 PMC1487984 Neurology

Full Text available with Trip Pro

1996 CMAJ: Canadian Medical Association Journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>